CoChat

Effectiveness of continuous glucose monitoring in patient management of Type 2 Diabetes Mellitus: an umbrella review of systematic reviews from 2011 to 2024

Tan, Yong Yi, Suan, Enhui, Koh, Gerald Choon Huat, Suhairi, Suhana Binte, Tyagi, Shilpa · 2024 · Archives of Public Health
Cited by 35

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13690-024-01459-2

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 98

  1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10:107–11. · DOI · Paper page
  2. Klein R, Klein BE. Relation of Glycemic Control to Diabetic Complications and Health Outcomes. Diabetes Care. 1998;21:C39–43. · DOI · Paper page
  3. Andersson DK, Svärdsudd K. Long-Term Glycemic Control Relates to Mortality in Type II Diabetes. Diabetes Care. 1995;18:1534–43. · DOI · Paper page
  4. Klonoff DC (2005) Continuous Glucose Monitoring. DIABETES CARE 28: · DOI · Paper page
  5. Mazze RS, Strock E, Wesley D, Borgman S, Morgan B, Bergenstal R, Cuddihy R. Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis. Diabetes Technol Ther. 2008;10:149–59. · DOI · Paper page
  6. Ong WM, Chua SS, Ng CJ. Barriers and facilitators to self-monitoring of blood glucose in people with type 2 diabetes using insulin: a qualitative study. Patient Prefer Adherence. 2014;8:237–46.
  7. Vettoretti M, Facchinetti A. Combining continuous glucose monitoring and insulin pumps to automatically tune the basal insulin infusion in diabetes therapy: a review. Biomed Eng OnLine. 2019;18:37. · DOI · Paper page
  8. Taylor PJ, Thompson CH, Brinkworth GD. Effectiveness and acceptability of continuous glucose monitoring for type 2 diabetes management: A narrative review. J Diabetes Investig. 2018;9:713–25. · DOI · Paper page
  9. ten Brinke R, Dekker N, de Groot M, Ikkersheim D. Lowering HbA1c in type 2 diabetics results in reduced risk of coronary heart disease and all-cause mortality. Prim Care Diabetes. 2008;2:45–9. · DOI
  10. Luk AOY, Ma RCW, Lau ESH, Yang X, Lau WWY, Yu LWL, Chow FCC, Chan JCN, So W-Y. Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry. Diabetes Metab Res Rev. 2013;29:384–90. · DOI · Paper page
  11. Ishibashi F, Taniguchi M, Kosaka A, Uetake H, Tavakoli M. Improvement in Neuropathy Outcomes With Normalizing HbA1c in Patients With Type 2 Diabetes. Diabetes Care. 2018;42:110–8. · DOI
  12. Genis-Mendoza AD, González-Castro TB, Tovilla-Vidal G, Juárez-Rojop IE, Castillo-Avila RG, López-Narváez ML, Tovilla-Zárate CA, Sánchez-de la Cruz JP, Fresán A, Nicolini H. Increased Levels of HbA1c in Individuals with Type 2 Diabetes and Depression: A Meta-Analysis of 34 Studies with 68,398 Participants. Biomedicines. 2022;10:1919. · DOI
  13. Arnold LW, Wang Z. The HbA1c and All-Cause Mortality Relationship in Patients with Type 2 Diabetes is J-Shaped: A Meta-Analysis of Observational Studies. Rev Diabet Stud RDS. 2014;11:138–52. · DOI · Paper page
  14. Wright LA-C, Hirsch IB (2017) Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters. Diabetes Technol Ther 19:S-16 · DOI · Paper page
  15. Monnier L, Wojtusciszyn A, Colette C, Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther. 2011;13:813–8. · DOI · Paper page
  16. Beyond A1C Writing Group. Need for Regulatory Change to Incorporate Beyond A1C Glycemic Metrics. Diabetes Care. 2018;41:e92–4. · DOI · Paper page
  17. Raj R, Mishra R, Jha N, Joshi V, Correa R, Kern PA. Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review. BMJ Open Diabetes Res Care. 2022;10:e002573. · DOI
  18. Lee I, Probst D, Klonoff D, Sode K. Continuous glucose monitoring systems - Current status and future perspectives of the flagship technologies in biosensor research -. Biosens Bioelectron. 2021;181:113054. · DOI · Paper page
  19. Di Molfetta S, Caruso I, Cignarelli A, Natalicchio A, Perrini S, Laviola L, Giorgino F. Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab. 2023;25:1301–10. · DOI
  20. Ang E, Lee ZX, Moore S, Nana M. Flash glucose monitoring (FGM): A clinical review on glycaemic outcomes and impact on quality of life. J Diabetes Complications. 2020;34: 107559. · DOI · Paper page
  21. Gao Y, Zhou M, Xu X, Chen WY. Effects of flash glucose monitoring on glycemic control in participants with diabetes mellitus: A meta-analysis of randomized controlled trials. J Diabetes Complications. 2022;36:108314. · DOI
  22. Asarani NAM, Reynolds AN, Boucher SE, de Bock M, Wheeler BJ. Cutaneous Complications With Continuous or Flash Glucose Monitoring Use: Systematic Review of Trials and Observational Studies. J Diabetes Sci Technol. 2020;14:328–37. · DOI · Paper page
  23. Ida S, Kaneko R, Murata K. Utility of Real-Time and Retrospective Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. J Diabetes Res. 2019;2019:e4684815. · DOI · Paper page
  24. Hoeks LBEA, Greven WL, de Valk HW. Real-time continuous glucose monitoring system for treatment of diabetes: a systematic review. Diabet Med. 2011;28:386–94. · DOI · Paper page
  25. Dicembrini I, Mannucci E, Monami M, Pala L. Impact of technology on glycaemic control in type 2 diabetes: A meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion. Diabetes Obes Metab. 2019;21:2619–25. · DOI · Paper page
  26. Gandhi GY, Kovalaske M, Kudva Y, et al. Efficacy of Continuous Glucose Monitoring in Improving Glycemic Control and Reducing Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized Trials. J Diabetes Sci Technol. 2011;5:952–65. · DOI · Paper page
  27. Pollock M, Fernandes R, Becker L, Pieper D, Hartling L Chapter V: Overviews of Reviews In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook.
  28. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. · DOI · Paper page
  29. Deeks JJ, Dinnes J, D’Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG, Group ISTC, Group ECSTC (2003) Evaluating non-randomised intervention studies. Health Technol Assess Winch Engl 7:iii–173 · DOI · Paper page
  30. Pérez-Bracchiglione J, Meza N, Bangdiwala SI, Niño de Guzmán E, Urrútia G, Bonfill X, Madrid E. Graphical Representation of Overlap for OVErviews: GROOVE tool. Res Synth Methods. 2022;13:381–8. · DOI · Paper page
  31. Tan BL, Tong HJ, Narashimhan S, Banihani A, Nazzal H, Duggal MS. Tooth autotransplantation: An umbrella review. Dent Traumatol. 2023;39:2–29. · DOI
  32. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat Softw. 2010;36:1–48. · DOI · Paper page
  33. Hariton E, Locascio JJ. Randomised controlled trials—the gold standard for effectiveness research. BJOG Int J Obstet Gynaecol. 2018;125:1716. · DOI · Paper page
  34. Baujat B, Mahé C, Pignon J-P, Hill C. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002;21:2641–52. · DOI · Paper page
  35. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94. · DOI · Paper page
  36. Aggarwal A, Pathak S, Goyal R. Clinical and economic outcomes of continuous glucose monitoring system (CGMS) in patients with diabetes mellitus: A systematic literature review. Diabetes Res Clin Pract. 2022;186:109825. · DOI
  37. Azhar A, Gillani SW, Mohiuddin G, Majeed RA. A systematic review on clinical implication of continuous glucose monitoring in diabetes management. J Pharm Bioallied Sci. 2020;12:102. · DOI
  38. García-Lorenzo B, Rivero-Santana A, Vallejo-Torres L, Castilla-Rodríguez I, García-Pérez S, García-Pérez L, Perestelo-Pérez L. Cost-effectiveness analysis of real-time continuous monitoring glucose compared to self-monitoring of blood glucose for diabetes mellitus in Spain. J Eval Clin Pract. 2018;24:772–81. · DOI
  39. Kieu A, King J, Govender RD, Östlundh L. The Benefits of Utilizing Continuous Glucose Monitoring of Diabetes Mellitus in Primary Care: A Systematic Review. J Diabetes Sci Technol. 2023;17:762–74. · DOI
  40. Meade LT. The use of continuous glucose monitoring in patients with type 2 diabetes. Diabetes Technol Ther. 2012;14:190–5. · DOI
  41. Park C, Le QA. The Effectiveness of Continuous Glucose Monitoring in Patients with Type 2 Diabetes: A Systematic Review of Literature and Meta-analysis. Diabetes Technol Ther. 2018;20:613–21. · DOI · Paper page
  42. Torres Roldan VD, Urtecho M, Nayfeh T, et al. A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia. J Clin Endocrinol Metab. 2023;108:592–603. · DOI
  43. Blackberry ID, Furler JS, Ginnivan LE, et al. An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study. Diabetes Res Clin Pract. 2014;106:247–55. · DOI
  44. Cai ZQ, Wu S. Observation on the effect of scanning glucose monitoring system in diabetic participants. Contemp Med. 2019;25:173–4.
  45. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline J-P, Rayman G. Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes. Diabetes Ther. 2017;8:573–86. · DOI · Paper page
  46. Liu Q, Xuan W, Zhang Z. Analysis of the effect of different blood glucose monitoring methods on blood glucose control in participants with type 2 diabetes mellitus. Med Innov China. 2020;17:136–9.
  47. Tildesley HD, Wright AM, Chan JHM, Mazanderani AB, Ross SA, Tildesley HG, Lee AM, Tang TS, White AS. A Comparison of Internet Monitoring with Continuous Glucose Monitoring in Insulin-Requiring Type 2 Diabetes Mellitus. Can J Diabetes. 2013;37:305–8. · DOI
  48. Yang HL. The application of ambulatory glucose monitoring in participants with type 2 diabetes mellitus. Med Forum. 2021;25:1031–3.
  49. Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019;42:1178–84. · DOI · Paper page
  50. Yeoh E, Lim BK, Fun S, Tong J, Yeoh LY, Sum CF, Subramaniam T, Lim SC. Efficacy of self-monitoring of blood glucose versus retrospective continuous glucose monitoring in improving glycaemic control in diabetic kidney disease patients. Nephrology. 2018;23:264–8. · DOI · Paper page
  51. Zhang W, Liu P, Ma SR, et al. The value of rapid glucose monitoring in participants with type 2 diabetes mellitus. Chin J Cardiovasc Rehabil. 2021;30:416–9.
  52. Zhang X, Yan Y, Peng L, et al. The application of transient scanning glucose monitoring system in elderly diabetic participants. Med Inf. 2021;34:180–2.
  53. Zhou M, Li X, Tu N, et al. The application of ambulatory glucose monitoring system in the management of type 2 diabetes mellitus. Chin J Prev Control Chronic Dis. 2021;29:700–2.
  54. Zhou M, Tu N, Xu X, et al. Effectiveness of FGMS-based combined health coaching techniques in the management of participants with type 2 diabetes mellitus. Chin J Gerontol. 2020;40:3839–43.
  55. Cosson E, Hamo-Tchatchouang E, Dufaitre-Patouraux L, Attali J-R, Pariès J, Schaepelynck-Bélicar P. Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay®) on glycaemic control in type 1 and type 2 diabetes patients. Diabetes Metab. 2009;35:312–8. · DOI · Paper page
  56. Ilany J, Bhandari H, Nabriski D, Toledano Y, Konvalina N, Cohen O. Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study. Diabetes Obes Metab. 2018;20:1186–92. · DOI
  57. Tang TS, Digby EM, Wright AM, Chan JHM, Mazanderani AB, Ross SA, Tildesley HG, Lee AM, White AS, Tildesley HD. Real-time continuous glucose monitoring versus internet-based blood glucose monitoring in adults with type 2 diabetes: A study of treatment satisfaction. Diabetes Res Clin Pract. 2014;106:481–6. · DOI
  58. Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM. Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients With Type 2 Diabetes. Diabetes Care. 2011;35:32–8. · DOI · Paper page
  59. Ajjan RA, Abougila K, Bellary S, Collier A, Franke B, Jude EB, Rayman G, Robinson A, Singh BM. Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients. Diab Vasc Dis Res. 2016;13:211–9. · DOI · Paper page
  60. Fantasia KL, Stockman M-C, Ju Z, Ortega P, Crable EL, Drainoni M-L, Walkey AJ, Bergstrom M, O’Brien K, Steenkamp D. Professional continuous glucose monitoring and endocrinology eConsult for adults with type 2 diabetes in primary care: Results of a clinical pilot program. J Clin Transl Endocrinol. 2021;24:100254.
  61. Kesavadev J, Vigersky R, Shin J, Pillai PBS, Shankar A, Sanal G, Krishnan G, Jothydev S. Assessing the Therapeutic Utility of Professional Continuous Glucose Monitoring in Type 2 Diabetes Across Various Therapies: A Retrospective Evaluation. Adv Ther. 2017;34:1918–27. · DOI
  62. Sato J, Kanazawa A, Ikeda F, et al. Effect of treatment guidance using a retrospective continuous glucose monitoring system on glycaemic control in outpatients with type 2 diabetes mellitus: A randomized controlled trial. J Int Med Res. 2016;44:109–21. · DOI · Paper page
  63. Thielen V, Scheen A, Bringer J, Renard E. Attempt to improve glucose control in type 2 diabetic patients by education about real-time glucose monitoring. Diabetes Metab. 2010;36:240–3. · DOI
  64. Speight J, Holmes-Truscott E, Thuraisingam S, et al. Impact of quarterly professional-mode flash glucose monitoring in adults with type 2 diabetes in general practice (GP-OSMOTIC): Secondary psychological and self-care outcomes of a pragmatic, open-label, 12-month, randomised controlled trial. Diabetes Res Clin Pract. 2021;179:108994. · DOI
  65. Taylor PJ, Thompson CH, Luscombe-Marsh ND, Wycherley TP, Wittert G, Brinkworth GD. Efficacy of Real-Time Continuous Glucose Monitoring to Improve Effects of a Prescriptive Lifestyle Intervention in Type 2 Diabetes: A Pilot Study. Diabetes Ther. 2019;10:509–22. · DOI · Paper page
  66. Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, Jackson RA. Assessing Psychosocial Distress in Diabetes: Development of the Diabetes Distress Scale. Diabetes Care. 2005;28:626–31. · DOI · Paper page
  67. Group TW. Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment. Psychol Med. 1998;28:551–8. · DOI · Paper page
  68. Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care. 1999;22:530–2. · DOI · Paper page
  69. Lind M, Odén A, Fahlén M, Eliasson B. The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia. 2010;53:1093–8. · DOI
  70. Antuna-Puente B, Disse E, Rabasa-Lhoret R, Laville M, Capeau J, Bastard J-P. How can we measure insulin sensitivity/resistance? Diabetes Metab. 2011;37:179–88. · DOI · Paper page
  71. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, Duncan AW. Diagnosing insulin resistance in the general population. Diabetes Care. 2001;24:460–4. · DOI · Paper page
  72. Edelman SV, Argento NB, Pettus J, Hirsch IB. Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring. Diabetes Care. 2018;41:2265–74. · DOI · Paper page
  73. Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract. 2001;18:565–8. · DOI · Paper page
  74. Probst P, Knebel P, Grummich K, Tenckhoff S, Ulrich A, Büchler MW, Diener MK. Industry Bias in Randomized Controlled Trials in General and Abdominal Surgery. Ann Surg. 2016;264:87–92. · DOI
  75. Lexchin J. Sponsorship bias in clinical research. Int J Risk Saf Med. 2012;24:233–42. · DOI
  76. Landefeld CS. Commercial support and bias in pharmaceutical research. Am J Med. 2004;117:876–8. · DOI
  77. Jin X, Yang X, Xu Y, et al. Differential correlation between time in range and eGFR or albuminuria in type 2 diabetes. Diabetol Metab Syndr. 2023;15:92. · DOI
  78. Gabbay MAL, Rodacki M, Calliari LE, et al. Time in range: a new parameter to evaluate blood glucose control in patients with diabetes. Diabetol Metab Syndr. 2020;12:22. · DOI · Paper page
  79. Dovc K, Battelino T. Time in range centered diabetes care. Clin Pediatr Endocrinol. 2021;30:1–10. · DOI
  80. Soni A, Wright N, Agwu J, et al. A practical approach to continuous glucose monitoring (rtCGM) and FreeStyle Libre systems (isCGM) in children and young people with Type 1 diabetes. Diabetes Res Clin Pract. 2022;184:109196. · DOI
  81. Crocket H, Elbashy MM, Kavanagh T, et al. Parental experiences of short term supported use of a do-it-yourself continuous glucose monitor (DIYrtCGM): A qualitative study. Diabet Med. 2022;39:e14731. · DOI
  82. Vloemans AF, van Beers C, a. J, de Wit M, Cleijne W, Rondags SM, Geelhoed-Duijvestijn PH, Kramer MHH, Serné EH, Snoek FJ,. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. Diabet Med. 2017;34:1470–6. · DOI
  83. Polonsky WH, Hessler D. What Are the Quality of Life-Related Benefits and Losses Associated with Real-Time Continuous Glucose Monitoring? A Survey of Current Users. Diabetes Technol Ther. 2013;15:295–301. · DOI · Paper page
  84. Litchman ML, Allen NA. Real-Time Continuous Glucose Monitoring Facilitates Feelings of Safety in Older Adults With Type 1 Diabetes: A Qualitative Study. J Diabetes Sci Technol. 2017;11:988–95. · DOI
  85. Messer LH, Johnson R, Driscoll KA, Jones J. Best friend or spy: a qualitative meta-synthesis on the impact of continuous glucose monitoring on life with Type 1 diabetes. Diabet Med. 2018;35:409–18. · DOI
  86. Steinberg E, Greenfield S, Wolman DM, Mancher M, Graham R, others (2011) Clinical Practice Guidelines We Can Trust. In: Institute Of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. National Academies Press
  87. Kataoka Y, Oide S, Ariie T, Tsujimoto Y, Furukawa TA. The Methodological Quality Score of COVID-19 Systematic Reviews is Low, Except for Cochrane Reviews: A Meta-epidemiological Study. Ann Clin Epidemiol. 2021;3:46–55. · DOI
  88. Siemens W, Schwarzer G, Rohe MS, Buroh S, Meerpohl JJ, Becker G. Methodological quality was critically low in 9/10 systematic reviews in advanced cancer patients—A methodological study. J Clin Epidemiol. 2021;136:84–95. · DOI
  89. Pandis N, Fleming PS, Worthington H, Salanti G. The Quality of the Evidence According to GRADE Is Predominantly Low or Very Low in Oral Health Systematic Reviews. PLoS ONE. 2015;10:e0131644. · DOI
  90. Beck RW. Closing in on closed-loop systems for type 2 diabetes. Nat Med. 2023;29:33–4. · DOI
  91. Thabit H, Hartnell S, Allen JM, Lake A, Wilinska ME, Ruan Y, Evans ML, Coll AP, Hovorka R. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes Endocrinol. 2017;5:117–24. · DOI · Paper page
  92. Boughton CK, Tripyla A, Hartnell S, Daly A, Herzig D, Wilinska ME, Czerlau C, Fry A, Bally L, Hovorka R. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med. 2021;27:1471–6. · DOI · Paper page
  93. Sharma P, Singh S, Thakur V, Sharma N, Grewal AS. Novel and emerging therapeutic drug targets for management of type 2 Diabetes Mellitus. Obes Med. 2021;23:100329. · DOI
  94. Yamada K, Nakayama H, Yoshinobu S, et al. Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring. J Diabetes Investig. 2015;6:699–707. · DOI
  95. Torimoto K, Okada Y, Koikawa K, Tanaka Y. Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring. Diabetol Metab Syndr. 2017;9:60. · DOI
  96. Hirsch IB, Parkin CG, Cavaiola TS, Bergenstal RM Use of continuous glucose monitoring when initiating glucagon-like peptide-1 receptor agonist therapy in insulin-treated diabetes. Diabetes Obes Metab. https://doi.org/10.1111/dom.15883 · DOI
  97. Abdelgadir E, Rashid F, Bashier A, Al Saeed M, Khalifa A, Alawadi F, Hassanein M. Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes. Diabetes Metab Syndr Clin Res Rev. 2019;13:2927–32. · DOI
  98. Hermanns N, Ehrmann D, Schipfer M, Kröger J, Haak T, Kulzer B. The impact of a structured education and treatment programme (FLASH) for people with diabetes using a flash sensor-based glucose monitoring system: Results of a randomized controlled trial. Diabetes Res Clin Pract. 2019;150:111–21. · DOI · Paper page

Cited by

See all 35

Metadata

Authors
Tan, Y. Y., Suan, E., Koh, G. C. H., Suhairi, S. B., & Tyagi, S.
Venue
Archives of Public Health
Published
2024-12-02
Volume
82
Issue
1
ISSN
2049-3258
Cited by
35
References
61
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.